

PTO/SB/08B (10-96)

Approved for use through 10/31/99, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Attorney Docket Number

Substitute for form 1449B/PTO NFORMATION DISCLOSURE TATEMENT BY APPLICANT

09/945,505 08/31/2001 **Application Number** Filing Date Alison E. Anastasio First Named Inventor 1634 Group Art Unit Goldberg Examiner Name

Complete if Known

MWH-0030US

(use as many sheets as necessary)

of | 1 sheet.

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
Examiner initials*	Cite No.1						
BA AKSENTIJEVICH 1, ""The Tumor-Necrosis-Factor Receptor-Associated Periodic Syndrome: New Mutations in TNFRSF1A, Ancestral Origins, Genotype-Phenotype Studies, and Evidence for Further Genetic Heterogeneity of Periodic Fevers," Am. J. Hum. Genet, Vol. 69 (No. 1), p. 301-314, (July 6, 200							
	BB	BRUCE AJ, "Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors," Nature Medicine, Vol. 2 (No. 7), p. 788-794, (July 5, 1996).					
	BC	HOHMANN H, "Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNFalpha)," J. Biol. Chem., Vol. 264 (No. 25), p. 14927-34, (September 5, 1989).					
1	BD	LUCKENBACH C et al., "Restriction fragment length polymorphism: Molecular weight analysis and calculation with a scanner-based computer system," Electrophoresis, Vol. 15, NO. 2, p. 149-152 (February 1994).					
	ВЕ	MCDERMOTT MF, "Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes," Cell. Vol. 97 ( No. 1), p. 133-144, (April 2, 1999).					
	BF	ROTHE J, "Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes," Nature. Vol. 364 (No. 1), p. 798-802. (August 26, 1993).					
	BG	SCHIEVELLA AR, "MADD, a Novel Death Domain Protein That Interacts with the Type 1 Tumor Necrosis Factor Receptor and Activates Mitogen-activated Protein Kinase," J. Biol. Chem., Vol. 272 (No. 18), p. 12069-75, (May 22, 1997).					
	Cy*						

Examiner Signature	8. Goldberg	Date Considered	8/22/03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.